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The molecular and functional diversity of G protein–coupled receptors is essential to many physiological processes. However,
this diversity presents a significant challenge to understanding the G protein–mediated signaling events that underlie
a specific physiological response. To increase our understanding of these processes, we sought to gain control of the timing
and specificity of Gs signaling in vivo. We used naturally occurring human mutations to develop two Gs-coupled engineered
receptors that respond solely to a synthetic ligand (RASSLs). Our Gs-coupled RASSLs are based on the melanocortin-4 receptor,
a centrally expressed receptor that plays an important role in the regulation of body weight. These RASSLs are not activated by
the endogenous hormone a-melanocyte-stimulating hormone but respond potently to a selective synthetic ligand,
tetrahydroisoquinoline. The RASSL variants reported here differ in their intrinsic basal activities, allowing the separation of
the effects of basal signaling from ligand-mediated activation of the Gs pathway in vivo. These RASSLs can be used to activate
Gs signaling in any tissue, but would be particularly useful for analyzing downstream events that mediate body weight
regulation in mice. Our study also demonstrates the use of human genetic variation for protein engineering.
Citation: Srinivasan S, Santiago P, Lubrano C, Vaisse C, Conklin BR (2007) Engineering the Melanocortin-4 Receptor to Control Constitutive and
Ligand-Mediated Gs Signaling In Vivo. PLoS ONE 2(8): e668. doi:10.1371/journal.pone.0000668
INTRODUCTION
G protein–coupled receptors (GPCRs) are the largest known
family of cell-surface receptors, encompassing ,350 distinct
members in mammals [1]. GPCRs play key roles in cellular
signaling to regulate many important physiological processes,
including cellular differentiation [2], immune response [3], smell
[4], taste [5], vision [6], heart rate regulation [7], learning and
memory [8], and energy homeostasis [9,10]. They are stimulated
by natural ligands, such as light, odorants, biogenic amines, lipids,
and peptide hormones. Upon activation, GPCRs transduce signals
by coupling to G proteins that modulate the intracellular
concentrations of second messenger systems, such as cAMP,
Ca
2+, and phospholipids, to effect sustained changes in transcrip-
tion and posttranslational modifications and ultimately alter the
physiology and behavior of an organism [11].
The diversity of receptors, ligands and G protein effector
systems that makes GPCRs biologically important also complicates
studies of their function in vivo. Standard methods for studying the
effects of a GPCR involve the administration of a ligand into
a tissue of interest. However, in a whole animal, receptor activation
cannot be restricted to a specific cell-type within a particular tissue.
In addition, several GPCRs belong to subfamilies that are
stimulated by the same ligand, but activate different downstream
pathways by coupling to different G protein families [12]. Finally,
the difficulty of monitoring the concentrations of endogenous
ligands in the tissue of interest has complicated the interpretation
of the studies of GPCR activation in vivo.
To circumvent these problems, we and others have developed
receptors called RASSLs, for Receptors Activated Solely by
a Synthetic Ligand; [9,13,14]. These engineered receptors are
insensitive to their natural endogenous ligands but can still be
activated by synthetic agonists. RASSL design is based on the
premise that endogenous peptide hormones bind at different sites
on the cognate receptors than do small-molecule synthetic ligands.
Such engineered receptors can be used to activate a G protein
pathway of interest rapidly and reversibly, mimicking the speed,
localization, regulation, and amplification of endogenous GPCR
signals. The resulting cellular and physiological changes are then
clearly attributable to the effects of the G protein pathway
activated by the RASSL. The first RASSL (RASSL opioid 1 or
Ro1) is Gi-coupled and based on the kappa opioid receptor [15].
Ro1 is unresponsive to physiological concentrations of opioid
peptides but is activated by nanomolar concentrations of the
selective synthetic ligand spiradoline. It has been used to study the
physiological effects of the Gi pathway in heart rate variability
[16], taste sensation [17], and olfactory perception [18]. We have
now generated Gs-coupled RASSLs based on the melanocortin-4
receptor (MC4R) for the study of Gs-mediated pathways in vivo.
The melanocortin receptor family consists of five members
(MC1R–MC5R) that are expressed in diverse mammalian tissues
and are involved in a wide range of physiological processes,
including the control of pigmentation, adrenal gland function,
inflammation, and energy homeostasis [19]. The melanocortin-4
receptor (MC4R) is primarily expressed in the mammalian brain,
plays an important role in body weight regulation [20], and is
a lead target for the treatment of obesity [21]. MC4R is stimulated
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MSH), transduces signal through the Gs protein, and activates
adenylyl cyclase to increase intracellular cAMP. MC4R also has
intrinsic basal activity that is suppressed by the inverse agonist
agouti-related peptide (AGRP) [22]. Numerous factors make
MC4R an excellent choice for Gs RASSL development. First, it is
exclusively coupled to Gs at physiologically relevant concentrations
of agonist [19], thus the effects of receptor activation can be clearly
attributed to the Gs pathway. Second, studies of naturally
occurring loss-of-function mutations in MC4R from obese subjects
[23–27], in conjunction with structure-function studies [28,29],
have identified several key regions of the receptor that are required
for binding of the endogenous ligand, a-MSH. Next, the role of
MC4R in the regulation of body weight has generated the interest
of pharmaceutical companies that have created potent small-
molecule agonists of MC4R to treat obesity and can be used to
activate an MC4R-based RASSL. Finally, AGRP and other
synthetic antagonists, such as SHU9119 [30,31], can be
administered to turn off the RASSL signal in vivo.
Here we report the generation of two MC4R-based RASSLs
and their properties with respect to their constitutive activities, the
potencies of endogenous and synthetic ligands, and their in-
ternalization properties. These RASSLs will be a powerful tool to
study the downstream effects of constitutive and ligand-mediated
Gs-signaling in vivo.
MATERIALS AND METHODS
MC4R Cloning and Mutagenesis
Wild-type MC4R was sequenced as described [32] and cloned into
the vector pcDNA 3.1 (Invitrogen, San Diego, CA). The prolactin
signal peptide, FLAG epitope tag, and green fluorescent protein
were added to the N-terminus of wild-type MC4R by standard
recombinant DNA methods, and all experiments described were
conducted using this construct as the wild-type control, since a-
MSH and THIQ showed the same efficacy and potency at this
receptor as at the MC4R cDNA alone. Point mutations in MC4R
were introduced with a site-directed mutagenesis kit (QuikChange,
Stratagene, La Jolla, CA) and sequenced to confirm the
substitutions. The DNA sequences corresponding to wild-type
MC4R, Rm1, and Rm2 can be found at http://www.gladstone.
ucsf.edu/gladstone/php/?sitename=conklin.
Cell Culture, Transfection, and the Generation of
Stable Cell Lines
HEK293 cells were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum containing L-
glutamine. Wild-type and mutant MC4R were transfected into
HEK 293 cells with Lipofectamine (Invitrogen). For the in-
ternalization assays, stable cell lines expressing wild-type or
RASSL-MC4R were generated by G418-mediated selection
(10 mg/ml) of clones expressing the neomycin-resistance gene
cotransfected with MC4R. Stable cell lines were maintained by
selection with 5 mg/ml G418.
cAMP Assays for MC4R Activity
cAMP production was measured with an ultra sensitive enzymatic
cAMP assay (CatchPoint, Molecular Devices, Sunnyvale, CA).
Transiently transfected cells were plated at 1610
5/well into 96-
well plates coated with poly-D-lysine (Sigma). Forty-eight h after
transfection, cells were rinsed in Krebs-Ringer bicarbonate buffer
containing glucose (Sigma) and incubated in pre-stimulation buffer
containing 0.75 mM 3-isobutyl-1-methylxanthine in the same
buffer for 10 min at room temperature. Cells were then stimulated
with forskolin, phosphate-buffered saline (basal conditions),
various concentrations of a-, b-, and c-MSH (natural agonists)
or tetrahydroisoquinoline (THIQ, synthetic agonist) for 2 h at
37uC. The cells were lysed, and cAMP accumulation was
measured according to the CatchPoint protocol. cAMP generated
under the different experimental conditions was interpolated from
a cAMP standard curve for each experiment. Four replicates were
used for each condition, and all experiments were repeated at
least three times. Emax and EC50 values were calculated with
SoftMax Pro. cAMP measurements were performed on transiently
transfected cells.
Detection of Membrane Expression of MC4R
Cell-surface expression of receptors was measured with an
enzyme-linked immunosorbent assay (ELISA) that detects the
extracellular FLAG tag. Transiently transfected cells were plated
at 1610
5/well into 96-well plates coated with poly-D-lysine
(Sigma). For internalization assays, cells were stimulated with the
indicated concentrations of a-MSH or THIQ for the times
indicated. Forty-eight h after transfection, cells were fixed in 4%
paraformaldehyde (Sigma) for 10 min at 4uC. After two washes in
phosphate-buffered saline, the cells were incubated in 1 mg/ml M1
anti-FLAG antibody (Sigma) for 2 h at room temperature, washed
twice in phosphate-buffered saline, and incubated for 1 h at room
temperature with horseradish peroxidase–conjugated goat-anti-
mouse (1:1000, BioRad, Chicago, IL). Cells were then washed
three times in phosphate-buffered saline, and 0.2 ml of 2,2-azino-
bis(3-ethylbenzthiazoline-6-sulfonic acid) liquid substrate (Sigma)
was added to each well. After 15–60 min, the optical density was
read at 405 nm in a spectrophotometer. Each experiment
included four replicates per condition and was repeated at least
three times.
RESULTS
Strategy for MC4-RASSL Construction
Heterozygous point mutations in MC4R account for 1–6% of
severe cases of human obesity. Over 50 different obesity-associated
mutations have been described, most of which are missense
mutations [23–27]. Point mutations in MC4R have been found in
all the domains of the receptor (Fig. 1). Mutated receptors have
impairments in ligand binding, internalization, or subcellular
localization. All these mutations reduce the ability of the receptor
to respond to a-MSH (data not shown and [26,32–34]. In
addition, structure-functions studies of MC4R have delineated the
role of three key acidic residues (E100A, D122A and D126A) in
transmembrane regions 2 and 3 (TM2 and 3) that are critical for
a-MSH binding and activation [28,29] (Fig. 1). By mapping the
point mutations on MC4R and correlating them with specific
defects in the receptor ([26,32–34] and data not shown), we found
that the majority of mutations buried in the TM regions and
intracellular loops led to the intracellular retention of the receptor.
To identify a receptor that was not activated by a-MSH, but still
activated by a synthetic ligand, with minimal loss of membrane
expression, we focused on five mutations (N97D, G98R, I102S,
L106P and S127L) in extracellular loop 1 (EL1) and three in its
flanking TM regions (E100A, D122A and D126A).
Point Mutations in EL1 Do Not Alter the Cell-Surface
Expression of MC4R
To examine the cell-surface expression of wild-type and mutant
MC4R, we performed ELISA on transiently transfected HEK293
A Gs-Coupled RASSL
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AGRP. Wild-type MC4R was expressed on the cell surface and
internalized after treatment with 1 mM a-MSH (Fig. 2), consistent
with previous reports [35]. The inverse agonist AGRP stabilized
receptor expression on the cell surface (Fig. 2). All point mutants
examined, that is, N97D, G98R, E100A, I102S, L106P, D122A,
D126A and S127L were relatively well-expressed at the cell
surface (i.e., 70–120% of that seen with the wild-type receptor)
(Fig. 2). With the exception of the S127L mutant, a-MSH was
unable to internalize the mutant receptors, suggesting that the
ligand fails to fully activate receptor signaling and initiate
desensitization and internalization.
MC4R EL1 Mutants Do Not Respond to a-MSH, but
Do Respond to the Synthetic Ligand THIQ
HEK293 cells transiently transfected with wild-type or mutant
MC4R were stimulated with increasing concentrations of a-MSH
or THIQ. Wild-type MC4R was activated by a-MSH with an
EC50 of 30.3 nM. Dose-response curves measuring cAMP
production showed that all five obesity-associated human muta-
tions in EL1, and point-to-point contact mutations in TM2 and
TM3 significantly reduced a-MSH-mediated activation (Fig. 3A).
The Emax of all mutated receptors was ,5% to 40% of wild-type
(Table 1); the EC50s of N97D, G98R, E100A, I102S, and L106P
could not be determined. The EC50s for D122A, D126A, and
S127L were in the mM range, well above the physiological range
of a-MSH in vivo (Table 1). The loss of a-MSH-mediated
activation in the human MC4R mutations is thought to be the
basis of the obesity in patients carrying these mutations.
We next determined the ability of these mutated receptors to
respond to the synthetic ligand THIQ, a selective MC4R agonist
that potently stimulates cAMP production in the wild-type
receptor in vitro [21] (EC50=3.5 nM) and the inhibition of food
intake in vivo. THIQ was synthesized as a peptidomimetic of the
potent a-MSH analog MT-II as a potential treatment for obesity
[36] and is approximately 30-fold more potent at MC4R than a-
MSH (Fig. 3 and Table 1). Interestingly, six of the seven mutations
tested were rescued by THIQ, albeit to different degrees (Fig. 3B
and Table 1). Notably, the human MC4R mutation L106P
generated a robust cAMP response to THIQ, with an EC50 of
24.2 nM, similar to that of a-MSH at wild-type MC4R
(EC50=30.3 nM). The D122A mutant, identified from struc-
ture-function studies of MC4R to be important for a-MSH
binding [28], also responded robustly to THIQ (EC50=29.5 nM).
These experiments identified two RASSLs, L106P-MC4R and
D122A-MC4R, which we designated RASSL MC4R 1 (Rm1)
and RASSL MC4R 2 (Rm2), respectively. We further analyzed
the potential for other amino acid substitutions (A, R, S, and W) at
positions L106 and L107 to yield a more potent response to
THIQ; however, these substitutions resulted either in mis-folded
receptors that were not expressed at the cell surface or in
receptors that did not show increased potency to THIQ (data not
shown).
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Compared to Wild-Type MC4R
MC4R has a well-documented intrinsic constitutive activity
(measured by cAMP accumulation in cells transfected with
MC4R in the absence of ligand) that can be suppressed by the
inverse agonist AGRP [22] (Fig. 4 and Table 1). When we
measured constitutive activity in all the EL1 mutants, we found
that E100A, D122A, and S127L, had higher constitutive activity
than the wild-type MC4R (Table 1). All mutants with increased
basal activity were close to the EL1/TM2 or EL1/TM3
boundaries. All other mutants showed slightly lowered constitutive
activity (Table 1) than wild-type MC4R. Rm1 had less AGRP-
suppressible basal activity than wild-type MC4R (Fig. 4A), even
though AGRP is a full antagonist when co-administered with
THIQ, suggesting that Rm1 has lower intrinsic basal activity.
Rm2 had a higher AGRP-suppressible basal activity than wild-
type MC4R (Fig. 4A). AGRP alone had no effect on mock-
transfected cells (Fig. 4A). The observed differences in basal
activity might have reflected subtle differences in membrane
expression. To exclude this possibility, we assessed basal activity by
expressing constitutive activity (as judged by cAMP accumulation)
as a ratio of cell-surface expression (as judged by ELISA) (Fig. 4B).
Again, the variation in the basal activities of Rm1 and Rm2,
compared to wild-type MC4R, were similar to those seen with
direct cAMP measurements (Fig. 4A and B). Since constitutive
signaling is important for normal GPCR function and altered
basal activity can result in pathological disease states [37,38], high-
basal and low-basal RASSL variants could have specific applica-
tions for the study of the physiological role of constitutive signaling
in vivo.
Rm1 and Rm2 Do Not Respond to Other Related
Endogenous Ligands
Proopiomelanocortin is a hypothalamic peptide that is post-
translationally cleaved by proconvertases to release the melano-
cortin peptides a-, b- and c-MSH, adrenocorticotropin and
endorphins [39]. In addition to the well-established role of a-
MSH in melanocortin receptor signaling, the related neuropep-
tides b-, and c-MSH are also ligands in vitro for the melanocortin
receptor family [40,41], although their physiological roles in vivo
are not well known. For full pharmacological control of Gs
activation in vivo, it is important to ensure that b- and c-MSH do
not activate Rm1 and Rm2 in an uncontrolled manner. To this
end, we measured cAMP release in transiently transfected cells
expressing wild-type MC4R, Rm1, and Rm2 in response to
increasing concentrations of b- and c-MSH (Fig. 5). b-MSH
elicited full activation of wild-type MC4R (EC50=2.78 nM), but
no activation at Rm1 and Rm2 (Fig. 5A). c-MSH did not activate
Rm1 or Rm2 and elicited a response with significantly weaker
potency from wild-type MC4R at high concentrations (1 mM;
Fig. 5B).
Internalization of MC4R, Rm1, and Rm2 in Response
to a-MSH and THIQ
As another measure of receptor activation, we examined ligand-
mediated internalization of MC4R, Rm1, and Rm2. We first
generated HEK293 cell lines stably expressing FLAG-tagged wild-
type MC4R and RASSLs. A 2-h exposure to increasing
concentrations of a-MSH sequestered MC4R in a dose-dependent
manner (maximal sequestration, ,60%). MC4R was sequestered
linearly over doses ranging from 1 nM to 1 mM (Fig. 6A), which
correlates well with the range in which Gs-mediated adenylyl
cyclase activation is detected (Fig. 3A). Rm1 and Rm2 did not
internalize in response to a-MSH, in keeping with the inability of
a-MSH to activate these RASSLs (Fig. 6B and C). Surprisingly,
a 2-h exposure to increasing concentrations of the synthetic ligand
THIQ did not cause sequestration of either wild-type MC4R,
Rm1, or Rm2 (Fig. 6A, B, C), even though similar concentrations
of THIQ activated both Rm1 and Rm2 as measured by cAMP
accumulation (Fig. 3).
We next examined the kinetics of internalization of MC4R as
measured by the loss of cell-surface MC4R expression. Treatment
of cells stably expressing MC4R with 1 mM a-MSH resulted in the
time-dependent internalization of the wild-type receptor. About
40% of receptors were internalized within 10 min and about 20%
over the next 80 min (Fig. 7A and [35]. After 4 h, the amount of
MC4R on the cell surface did not decrease further (not shown),
indicating that the rate of internalization of MC4R is at
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the dose-response experiments (Fig. 6), addition of 1 mM THIQ
did not result in internalization of wild-type MC4R during a 2-h
exposure (Fig. 7A). Rm1 and Rm2 were not internalized in
response to a-MSH during either a 2-h (Fig. 7B and C) or 4-h
exposure (not shown). Although Rm1 did not internalize in
response to 1mM THIQ, we observed an approximately 20%
decrease in the cell-surface expression of Rm2 in response to the
same concentration of THIQ.
DISCUSSION
We developed two Gs-coupled RASSLs based on the MC4R.
Rm1 and Rm2 were generated by identifying mutations in MC4R
that were unresponsive to the endogenous ligand a-MSH but were
still fully responsive to the high-affinity MC4R-selective synthetic
ligand THIQ. Rm1 and Rm2 are well-expressed at the cell-surface
and do not respond to other endogenous ligands, such as b- and c-
MSH. This and other studies [28,32] indicate that EL1, TM2, and
TM3 are critical regions for a-MSH-mediated activation of
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..................................................................................................................................................
Construct Basal Activity (% of WT) a-MSH activation THIQ activation
Emax (% of WT) EC50 (nM) Emax (% of WT) EC50 (nM)
WT MC4R 100 100 30.365.0 100 0.860.3
N97D 92.964.0 7.762.3
a 43.163.1
G98R 99.3619.2 2.460.8
a 2.660.6
a
E100A 123.063.4 13.662.2
a 44.5464.9
a
I102S 89.861.1 11.961.6
a 49.262.2
a
L106P (Rm1) 71.266.8 10.260.5
a 73.4614.8 2.460.9
D122A (Rm2) 185.8622.8 19.861.2
a 90.366.2 2.960.5
D126A 69.667.5 21.360.4
a 50.763.6
a
S127L 149.5613.3 38.362.0
a 21.763.5
a
Values are mean6s.e.m. (n$3).
aEC50 could not be determined. WT, wild-type.
doi:10.1371/journal.pone.0000668.t001
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least a partial response when key residues in these regions are
mutated. An important difference between the two RASSLs
reported here lies in their intrinsic constitutive activities. Rm1 has
a low constitutive activity (75% of wild-type), and Rm2 has high
constitutive activity (140% of wild-type). This variation may be
particularly advantageous for studying the physiological conse-
quences of constitutive signaling. For example, loss of basal activity
of MC4R is associated with human obesity (Srinivasan et al.,
2004), and increased basal Gs signaling has been associated with
increased cell proliferation and tumor formation in the pituitary
[37] and other endocrine glands [42]. Thus, the ability to
modulate basal signaling offers a unique opportunity to separate
the physiological contribution of basal signaling versus ligand-
mediated GPCR activation in vivo. In addition, since THIQ is able
to elicit a partial response from some mutated MC4Rs, our
findings suggest that THIQ may be a potential obesity therapeutic
for people carrying MC4R mutations.
The differences in internalization of wild-type MC4R, Rm1, and
Rm2 in response to a-MSH and THIQ are particularly interesting.
Dose-response curves measuring adenylyl cyclase activation and
cAMP generation showed that THIQ is 30-fold more potent than a-
MSH at MC4R. This increased potency may reflect the lower
internalization rate of MC4R in response to THIQ than to a-MSH.
Further studies on agonist-selective internalization of MC4R will be
required to elucidate the precise mechanistic explanation for these
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Figure 5. Wild-type MC4R, Rm1, and Rm2 were transiently transfected into HEK293 cells, which were stimulated with increasing concentrations
of b-MSH (A) or of c-MSH (B), and cAMP was measured to generate dose-response curves. Data shown are mean6s.e.m. of quadruplicate
determinations. The dose-response curves are representative of two independent experiments.
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PLoS ONE | www.plosone.org 7 August 2007 | Issue 8 | e668effects. Agonist-selective internalization has certainly been demon-
strated for other GPCRs. For example, the Gi-coupled k-opioid
receptor is internalized within 30 min in response to physiological
concentrations of the alkaloid agonist etorphine and its synthetic
analog, DAMGO [43]. However, it is insensitive to internalization
by the analgesic morphine at concentrations far greater than
required to inhibitadenylylcyclasevia themuopioidreceptor. It will
be interesting to further explore the molecular basis of agonist-
selective internalization at MC4R and to identify potential
differences in phosphorylation by GRKs or arrestin binding that
underlie this observation.
The concept of designing engineered receptors as tools to
control signal transduction pathways in vivo was first used to make
‘‘designer dimerizers’’ [44]. An intracellular growth factor receptor
domain was fused to an extracellular drug-binding protein
domain. The binding of a synthetic chemical dimerizer resulted
in the reversible dimerization of the fusion protein, which then
triggers a cascade of downstream signaling events. This system has
been successfully used to control proliferation in many cell types,
including myoblasts, hepatocytes, and hematopoetic stem cells
[44–46]. For signaling engineering in GPCRs, a designer b-
adrenergic receptor was developed by Small and colleagues [47].
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Figure 6. HEK293 cells stably expressing wild-type MC4R (A), Rm1 (L106P) (B), and Rm2 (D122A) (C) were exposed to increasing concentrations
of a-MSH or THIQ for 2 h. Cell-surface FLAG-tagged receptors were measured by ELISA. Receptor sequestration was calculated as the loss of receptor
expression from the cell surface. Wild-type MC4R was internalized significantly more (p,0.05) in response to a-MSH than THIQ at doses of 10
27 M
and higher. Data represent the mean6s.e.m. of two independent experiments, each performed in quadruplicate.
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PLoS ONE | www.plosone.org 8 August 2007 | Issue 8 | e668A synthetic ligand-binding site was engineered into TM3 of the
receptor, and the C-terminal tail was truncated and fused to the
Gas protein. The two-way selection this provided allowed targeted
activation of the receptor upon ligand binding. Although elegant,
the system was of limited use because the potency of the ligand was
too low (EC50 in mM range) for systemic administration of the
ligand in mice. The RASSL concept circumvents the task of
engineering a new ligand binding site, since preexisting high-
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Figure 7. HEK293 cells stably expressing wild-type MC4R (A), Rm1 (B), and Rm2 (C) were exposed to 1 mM a-MSH or THIQ for the times
indicated. Cell-surface FLAG-tagged receptors were measured by ELISA. Receptor internalization was calculated as the loss of receptor expression
from the cell surface. After 60 min, significantly more wild-type MC4R was internalized (p,0.05) in response to a-MSH than THIQ. Data represent the
mean6s.e.m. of two independent experiments, each performed in quadruplicate.
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addition to the Gi and Gs RASSLs developed in our laboratory
[15], a Gs-coupled RASSL was recently developed using the 5HT-
4 receptor [14]. It will be interesting to compare Gs-mediated
signaling from the RASSLs based on the 5HT-4 receptor and the
MC4R for receptor-specific differences in Gs protein activation in
the same cell types in vivo.
The most immediate application of the MC4R-based RASSLs
lies in their use as Gs switches for studies of food-intake and body-
weight regulation in mice. Experiments based on peripherally
administered a-MSH have delineated a role for MC4R in these
processes [19]. However, a detailed, mechanistic understanding of
the cellular and biochemical changes in the hypothalamus in
response to MC4R signaling has been difficult to elucidate because
of the presence of the endogenous hormone, a-MSH, and MC3R
(also activated by a-MSH), which may contribute to the
maintenance of energy homeostasis [48–50]. The observation
that loss-of-function mutations in MC4R are often correlated with
early-onset obesity [32] suggests that MC4R plays a role during
neonatal life, however its selective role in adulthood can be
evaluated in MC4-RASSL knock-in transgenic mice. In addition,
the recent demonstration of the trophic actions of leptin in
mediating synapse formation and plasticity in the hypothalamus
[51] suggests that MC4R, a critical downstream component of the
leptin pathway, may mediate these effects. A targeted gene knock-
in approach in mice could be used to replace the genomic copies of
the endogenous receptor with Rm1 or Rm2. Alternatively,
retrovirus-mediated hypothalamic expression of RM1 and Rm2
in adult MC4R-deficient mice could be used as a first step in
evaluating Rm1 and Rm2 in vivo. Since Rm1 possesses low basal
activity, it would produce less cAMP than the wild-type receptor,
and the phenotype of the mice expressing Rm1 (predicted to be
overweight compared to wild-type mice) can be used to determine
the functional contribution of MC4R basal signaling. Conversely,
Rm2 has high basal signaling and would be predicted to reduce
body weight. Administration of THIQ can then be used to
separate the effects of ligand-mediated versus basal signaling in the
specific MC4R-expressing neurons at different times during pre-
and postnatal development to elucidate the contribution of
MC4R-mediated Gs signaling in synaptic plasticity and other
downstream events required to maintain energy homeostasis.
Having two RASSLs with different basal activities would be
especially useful because in vitro and indirect in vivo [52] evidence
suggest that the basal activity of MC4R may also be important
these processes.
Traditional biochemical studies of receptor function have used
site-directed or saturation mutagenesis to assess structure-function
relationships for the role of individual amino acids in conserved
protein domains, and such studies have been very useful towards
our current understanding of protein function. Novel strategies
using in silico methods that employ the knowledge of coevolved
energetically coupled residues have also yielded valuable in-
formation on functionally important surfaces required for ligand
binding in receptors of previously unknown function [53,54]. The
study presented here has hinged on the availability of human
genetic data, where substitution of functionally important residues
is correlated with a loss-of-function disease phenotype. In the
absence of high-resolution structural information for GPCRs, this
knowledge rapidly allows one to target those regions most likely to
be useful for receptor engineering. Even though the MCR4
mutations we studied are relatively rare (,5% of severe obesity),
the obesity phenotype allowed them to be identified and rapidly
tested for the biochemical consequences of the mutation. As we
gain a better understanding of genotype-phenotype correlations
for other genes, it may be possible to find other collections of rare
point mutations that result in human phenotypic variation. The
MC4R provides a model of how a detailed understanding of
human genetics can be used as a powerful tool for protein
engineering.
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